Chargement en cours...
Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma
Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting m...
Enregistré dans:
| Publié dans: | Mol Ther Oncolytics |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Gene & Cell Therapy
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7327877/ https://ncbi.nlm.nih.gov/pubmed/32637583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2020.06.001 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|